Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1522764

	registered interest
	date	17/10/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Voluntary scheme for branded medicines pricing and access, whether her Department has made an assessment of the potential merits of an exemption from payments for new active substances from that scheme.
	tabling member constituency	Harlow
	tabling member printed	Robert Halfon
	uin	64035
	answer	answer is ministerial correction date of answer 25/10/2022 answer text <p>The Voluntary Scheme for Branded Medicines Pricing and Access includes a 36 month exemption from payments for drugs containing a new active substance, starting once the marketing authorisation has been granted. Treatment of new active substances under a future voluntary scheme is subject to negotiation.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 25/10/2022 16:47:32 answering member 4320 label Biography information for Robert Jenrick
	tabling member	3985 label Biography information for Robert Halfon

1521787

	registered interest
	date	13/10/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make it her policy to publish data comparing the voluntary scheme for branded medicines pricing and access repayments against leading European countries with similar access or rebate schemes in each year since 2015.
	tabling member constituency	Harlow
	tabling member printed	Robert Halfon
	uin	62791
	answer	answer is ministerial correction date of answer 25/10/2022 answer text <p>We have no plans to do so.</p><p>Prices paid for medicines internationally are generally confidential. It is therefore not possible to make an accurate comparison of the net price of medicines between the UK and other countries, with or without rebate rates.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 25/10/2022 14:51:43 answering member 4320 label Biography information for Robert Jenrick
	tabling member	3985 label Biography information for Robert Halfon

1521789

	registered interest
	date	13/10/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make a comparative estimate of the annual savings that (a) unbranded generic, (b) branded generic and (c) biosimilar medicines have contributed to the NHS drug bill compared to branded prices had those medicines not been available for each year since 2012 for which data is available.
	tabling member constituency	Harlow
	tabling member printed	Robert Halfon
	uin	62793
	answer	answer is ministerial correction date of answer 25/10/2022 answer text <p>The current Voluntary Scheme for Branded Medicines Pricing and Access expenditure forecast assumes that average spend at patent expiry will decrease by 70% for a non-biologic medicine or 45% for a biologic medicine. The Secretary of State has also commissioned further policy advice on this matter. These assumptions will be reviewed ahead of the negotiation of a new Scheme.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 25/10/2022 14:44:42 answering member 4320 label Biography information for Robert Jenrick
	tabling member	3985 label Biography information for Robert Halfon